Opus Genetics: RDF sells 556,000 common shares

Opus Genetics, Inc. (IRD) reporting person Foundation Fighting Blindness Retinal Degeneration Fund (RDF) sold 556,000 common shares on September 30, 2026, at a weighted average price of $4.9568 per share; multiple trades ranged from $4.95 to $5.29.

Rhea-AI Filing Summary

Opus Genetics, Inc. (IRD) reporting person Foundation Fighting Blindness Retinal Degeneration Fund (RDF) sold 556,000 common shares on September 30, 2026, at a weighted average price of $4.9568 per share; multiple trades ranged from $4.95 to $5.29. RDF reported 3,236,171 shares following the sale. No Rule 10b5-1 plan is reported. The reporting persons may be deemed directors by deputization after Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to Opus Genetics' board.

Insider Trade Summary

Net Seller: 556,000 shares

Net Sell 1 txn

Insider Foundation Fighting Blindness Retinal Degeneration Fund, Foundation Fighting Blindness, Inc.

Role Director | Director

Sold 556,000 shs ($2.76M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	556,000	$4.9568	$2.76M

Holdings After Transaction: Common Stock — 3,236,171 shares (Direct)

Footnotes (2)

1. F1. This transaction was executed in multiple trades at prices ranging from $4.95 to $5.29. The price reported in Column 4 is a weighted average price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
2. F2. Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold.

Key Figures

Common shares sold: 556,000 shares Weighted average price: $4.9568 per share Trade price range: $4.95 to $5.29 per share +1 more

4 metrics

Common shares sold 556,000 shares September 30, 2026

Weighted average price $4.9568 per share Sale on September 30, 2026

Trade price range $4.95 to $5.29 per share Multiple trades

Shares following transaction 3,236,171 shares RDF's reported position after the sale

Key Terms

weighted average price, director by deputization, beneficially own

3 terms

weighted average price financial

"Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

director by deputization regulatory

"may be deemed a director by deputization"

beneficially own regulatory

"may be deemed to beneficially own the securities"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Opus Genetics (IRD) shares did RDF sell, and at what price?

Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 common shares on September 30, 2026, at a weighted average price of $4.9568 per share. The multiple trades ranged from $4.95 to $5.29, and no Rule 10b5-1 plan is reported.

How many Opus Genetics (IRD) shares did RDF hold after the sale?

Foundation Fighting Blindness Retinal Degeneration Fund reported 3,236,171 shares following the sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 07:47 PM Accepted by SEC EDGAR 10/02/2026 - 07:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foundation Fighting Blindness Retinal Degeneration Fund

(Last) (First) (Middle)

223 S. WEST STREET, SUITE 900

(Street)

RALEIGH NORTH CAROLINA 27603

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2026		S		556,000	D	$4.9568(1)	3,236,171	D(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Foundation Fighting Blindness Retinal Degeneration Fund

(Last) (First) (Middle)

223 S. WEST STREET, SUITE 900

(Street)

RALEIGH NORTH CAROLINA 27603

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

1. Name and Address of Reporting Person^*

Foundation Fighting Blindness, Inc.

(Last) (First) (Middle)

6925 OAKLAND MILLS ROAD, #701

(Street)

COLUMBIA MARYLAND 21045

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $4.95 to $5.29. The price reported in Column 4 is a weighted average price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

2. Foundation Fighting Blindness, Inc. ("FFB") is the sole member of Foundation Fighting Blindness Retinal Degeneration Fund ("RDF") and may be deemed to beneficially own the securities owned directly by RDF. RDF has the power to vote and dispose of any securities directly owned by RDF. RDF's board of directors makes voting and investment decisions regarding securities held by RDF, subject to certain approval rights of the board of directors of FFB with respect to transactions exceeding a certain threshold.

Remarks:

For purposes of Section 16 of the Exchange Act of 1934, as amended, the Reporting Persons may be deemed a director by deputization of Issuer by virtue of the fact that Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to serve on the board of directors of Issuer and Dr. Graves is the chair of the board of directors of RDF and a member of the board of directors of FFB and Dr. Bennett is a member of the board of directors of RDF.

	Foundation Fighting Blindness Retinal Degeneration Fund, By: /s/ Russell Kelley, Name/Title: Russell Kelley, Managing Director	10/02/2026
	Foundation Fighting Blindness, Inc., By: /s/ Jason Menzo, Name/Title: Jason Menzo, Chief Executive Officer	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)